相关实验视频
Updated: Jul 1, 2026

07:45
Acute Myocardial Infarction in Rats
Published on: February 16, 2011
53.5K
在急性心肌缺血模型中,花莲提取物对凝血功能的影响
Zhanwang Zhu1, Shifang Mo2, Jinxia Luo3
1Department of Hematology, Zhuzhou Central Hospital, No. 116 Changjiang South Road, Tianyuan District, Zhuzhou, 412000, Hunan, China.
Thrombosis journal
|August 26, 2025
概括
在急性心肌缺血 (AMI) 的老鼠模型中,花提取物 (GE) 改善了心脏功能和凝血. 转基因治疗逆转了心肌损伤,炎症和氧化应激,为AMI提供了潜在的治疗益处.
科学领域:
- 心血管研究
- 药理学
- 传统医学
背景情况:
- 急性心肌缺血 (AMI) 是一种严重的疾病,其特征是心脏功能受损和血栓形成的风险增加.
- 凝血功能障碍是AMI的一个显著并发症,加剧心肌损伤.
- 果提取物 (GE) 源自果 jasminoides,传统上用于其抗炎和抗氧化特性.
研究的目的:
- 在急性心肌缺血 (AMI) 的小鼠模型中研究花莲提取物 (GE) 对凝血功能的治疗作用.
- 评估GE对心脏功能,心肌损伤,炎症和氧化应激的影响.
- 确定GE对这些参数的剂量依赖性影响.
主要方法:
- 用AMI诱导大鼠,并用不同剂量的GE (低,中,高) 或载体治疗.
- 使用心声扫描 (LVEF,LVFS,LVEDD,LVESD) 评估心脏功能.
- 分析了心肌病理,亡,炎症,氧化应激和凝血参数 (PT,TT,PTR,INR,FIB).
主要成果:
- AMI导致心肌损伤,心脏功能受损和凝血功能障碍 (PTR增加).
- 转基因治疗显著改善了心脏功能,并扭转了心肌损伤.
- 根据剂量,GE的使用改善了凝血功能 (增加了TT,PT,FIB,INR),并降低了炎症和氧化应激标志物.
结论:
- 在改善与AMI相关的心脏功能和凝血异常方面,花提取物具有显著的治疗潜力.
- 在AMI模型中,GE有效减轻心肌损伤,炎症和氧化应激.
- 这些发现表明GE是治疗急性心肌缺血的一个有前途的天然化合物.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

